CeriBell (NASDAQ:CBLL) Trading Down 2.6% – Time to Sell?

CeriBell (NASDAQ:CBLL)’s stock price was down 2.6% on Thursday . The stock traded as low as $26.28 and last traded at $26.29. Approximately 85,309 shares changed hands during trading, a decline of 65% from the average daily volume of 246,355 shares. The stock had previously closed at $26.98.

Analyst Ratings Changes

CBLL has been the topic of a number of recent analyst reports. Canaccord Genuity Group began coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock. William Blair began coverage on CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. TD Cowen lifted their price target on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Bank of America began coverage on CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.60.

CeriBell Trading Down 2.6 %

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. Analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.